Side Effects of temozolomide injection: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of temozolomide injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of temozolomide injection: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of temozolomide injection: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main research findings

Temozolomide is an anticancer drug that plays a vital role in glioblastoma (GBM) treatment. Several studies have investigated the effectiveness of temozolomide alone or in combination with other therapies. 11 showed that systemic temozolomide combined with locally delivered mitoxantrone can potentially prolong survival in patients with recurrent GBM. 3 presented a new approach involving the delivery of paclitaxel directly to brain tumors in addition to temozolomide, suggesting a potential effective treatment for GBM. 5 indicated that combining convection-enhanced delivery (CED) of temozolomide directly to brain tumors with immunotherapy could improve therapeutic effects of GBM. Also, 8 demonstrated that the combination of temozolomide and retinoids might improve therapeutic effects of GBM. These studies suggest that temozolomide is effective in treating GBM, but the risk of side effects needs to be considered.

Reason for side effects

Temozolomide is a type of alkylating agent that inhibits cancer cell growth by damaging DNA. This mechanism of action can affect both cancer cells and normal cells, leading to side effects. The severity of temozolomide side effects varies depending on the dose, duration of administration, and patient's health status.

Common side effects

Gastrointestinal

Temozolomide can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and loss of appetite. 10 reported gastrointestinal side effects in patients who received temozolomide and interleukin-2 combination therapy.

Hematologic

Temozolomide can cause side effects that decrease the number of white blood cells and platelets. 10 reported thrombocytopenia in patients who received temozolomide and interleukin-2 combination therapy.

Neurological

Temozolomide can cause neurological side effects such as headache, dizziness, and fatigue. 11 reported mild neurological side effects in patients who received local administration of temozolomide.

Other side effects

Temozolomide can cause side effects such as hair loss, rash, taste changes, and liver dysfunction.

Measures against side effects

Gastrointestinal

Dietary therapy and drug therapy such as antiemetics are used to reduce gastrointestinal side effects.

Hematologic

Drug therapy such as hematopoietic growth factors are used to reduce hematologic side effects.

Neurological

Drug therapy such as analgesics is used to reduce neurological side effects.

Other side effects

Appropriate treatment is selected according to the symptoms to reduce other side effects.

Comparison between studies

Common points of the studies

These studies suggest that temozolomide is effective in treating GBM.

Differences between the studies

These studies differed in administration methods, combination drugs, and evaluation criteria. Therefore, it is not possible to directly compare the research results.

Precautions for application in real life

Temozolomide is an anticancer drug effective for treating GBM. However, it is necessary to consider the risk of side effects. Temozolomide should be used under the guidance of a doctor.

Limitations of current research

There is not enough research on temozolomide yet. Further research is needed to improve the therapeutic efficacy of GBM and reduce side effects.

Future research directions needed

The following research is considered necessary to gain a deeper understanding of the efficacy and safety of temozolomide.

  • Optimization of temozolomide administration methods
  • Development of combination therapies of temozolomide and other therapies
  • Development of methods for preventing and treating temozolomide side effects

Conclusion

Temozolomide is an important anticancer drug in GBM treatment. However, it is necessary to consider the risk of side effects. Temozolomide should be used under the guidance of a doctor. Future research is expected to further clarify the efficacy and safety of temozolomide.

Literature analysis of 12 papers
Positive Content
10
Neutral Content
1
Negative Content
1
Article Type
0
1
1
1
12
1.

Injectable local drug delivery systems for glioblastoma: a systematic review and <i>meta</i>-analysis of progress to date.

Author: WangYu, BastiancichChiara, NewlandBen

GBM treatment
Increased survival time
Reduced systemic side effects
No DDS clinically approved

This review explores the development and pre-clinical testing of injectable drug delivery systems (DDS) for local treatment of glioblastoma. The analysis of 36 original articles showed that local administration of injectable DDS was beneficial in increasing animal survival time, suggesting promising potential for future clinical translation.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Injectable diblock copolypeptide hydrogel provides platform to deliver effective concentrations of paclitaxel to an intracranial xenograft model of glioblastoma.

Author: GarrettMatthew C, O'SheaTimothy M, WollenbergAlexander L, BernsteinAlexander M, HungDerek, StaarmanBrittany, SotoHoracio, DemingTimothy J, SofroniewMichael V, KornblumHarley I

Inaccessible tumor location
Limited efficacy
Poor health status

Temozolomide is a standard treatment for glioblastoma, but it has limited efficacy and many patients are not candidates for surgery.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma.

Author: Da RosMartina, IorioAnna Lisa, De GregorioVeronica, FantappièOrnella, LaffiGiacomo, de MartinoMaurizio, PisanoClaudio, GenitoriLorenzo, SardiIacopo

GBM treatment

This study evaluated the effectiveness of Aldox combined with TMZ in preclinical models of Glioblastoma Multiforme.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Inhibiting constitutive neurogenesis compromises long-term social recognition memory.

Author: Pereira-CaixetaAna Raquel, GuarnieriLeonardo O, MedeirosDaniel C, MendesEduardo M A M, LadeiraLuiz C D, PereiraMárcio T, MoraesMárcio F D, PereiraGrace S

Social recognition memory
Neurogenesis inhibition
Side effects

This study investigated the effects of inhibiting constitutive neurogenesis on social recognition memory (SRM) in mice. The researchers found that inhibiting neurogenesis, using different methods, impaired SRM.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.

Author: MasucciGiuseppe Valentino, Månsson-BrahmeEva, Ragnarsson-OldingBoel, NilssonBo, WageniusGunnar, HanssonJohan

Melanoma treatment
Brain metastases
Thrombocytopenia

Temozolomide, a chemotherapeutic agent, in combination with low-dose recombinant human interleukin-2 was found to be a well-tolerated regimen for outpatient treatment of metastatic malignant melanoma. The combination induced durable clinical responses, with thrombocytopenia potentially being a predictive factor for response to therapy.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

Author: BoiardiA, EoliM, SalmaggiA, LampertiE, BotturiA, BroggiG, BissolaL, FinocchiaroG, SilvaniA

GBM treatment
Neurological side effects

This study evaluated the use of local chemotherapy delivery with a Rickam reservoir in patients with recurrent glioblastoma multiforme (GBM). The median progression-free survival and overall survival were similar to those reported in the literature for recurrent GBM.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

Author: GogasHelen, BafaloukosD, AravantinosG, FountzilasG, TsoutsosD, PanagiotouP, FrangiaK, KalofonosH P, BriasoulisE, CastanaO, PolyzosA, PectasidesD, IoannovichJ,

Clinical benefit
Flu-like symptoms

The combination of vinorelbine and IL-2 provided clinical benefit in patients recurring or progressing on first-line chemotherapy for metastatic melanoma. The most common side effects were flu-like symptoms.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.